 |
||||||||||||||||||||
|
|
|||||||||||||||||||
 |
 |
 |
 |
|
||||||||||||||||
| Bremelanotide was Palatin Technologies drug candidate for treatment of male and female sexual dysfunction. It has been replaced with PL-6983 which causes significantly lower blood pressure increase. Click here for our "Bremelanotide Bulletin" |
|
|||||||||||||||||||
 |
|
|||||||||||||||||||
 |
 |
|
||||||||||||||||||
| A biopharmaceutical company focused on discovering and developing melanocortin (MC)-based therapeutics. In the near future it will begin clinical trials with PL-6983, the replacement drug for Bremelanotide, to treat both male & female sexual disorders. |
|
|||||||||||||||||||
 |
|
|||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
|
|||||||||||||
|
MSNBC.com - Boosts women's sex drive... stimulates brain arousal. ABC News (KITV) - Viagra Type Drug For Women Closer To Reality. Wired - Would you inhale to boost your sex drive? Salon Magazine - Do women want a sex-drive drug? Pherlure - University Tested and Proven Pheromones. Click 'Pherlure' for more info. |
First came Viagra, which gave men the physical ability to you know what ... But being ABLE to ... doesn't necessarily mean you WANT to. Science to the rescue! If a woman has sex with a man that she wouldn't normally let within 10 feet of her just because he slipped her a pill that made her horny, is that consent..? |
 |
|
|||||||||||||||||
|
MOST RECENT POST: SUBSCRIBE TO THE BREMELANOTIDE BULLETIN - The latest News & Opinions and when you can buy it! |
|
|||||||||||||||||||
|
|
||||||||||||||||||||
 |
||||||||||||||||||||
|
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
 |
|
|||||||||||||||||||
|
Home
| Palatin Technologies | PL-6983 Aphrodisiac |
Bremelanotide Bulletin |
Contact Us Bremolanotide.com is a subsidiary of Arcana Media and not affiliated with Palatin Technologies. "Bremolanotide" was the spelling used for Bremelanotide in a number of news releases on and around May 2006, which were the origins for this domain name. |
|
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||